Get More DONE.
Driving Strategy, Compliance, and Growth.

We help clients define the most efficient regulatory pathway for their combination products. Our team supports regulatory assessments, filing option evaluations, and product designation strategies, including pre-RFDs/RFDs. We also guide expedited review applications such as Orphan Designation and Fast Track, and prepare clients for FDA interactions through strategic planning, briefing book development, and pre- and post-meeting support.

Kymanox provides expert support for global submissions, including INDs, BLAs, NDAs, and 510(k)s. Our team ensures that technical documentation is complete, compliant, and aligned with regulatory expectations to streamline approval and avoid delays.

Kymanox helps clients expand worldwide by managing Notified Body interactions, NBOp authoring and submissions, and regional regulatory engagement. With experience across FDA, EMA, MHRA, PMDA, and other global authorities, we ensure combination products are positioned for successful approval and distribution across multiple markets.

Combination products require ongoing regulatory oversight well beyond initial approval. We support lifecycle management activities such as design and process changes, documentation updates, and supplementary filings to keep products in compliance and on the market.

Our regulatory experts continuously monitor evolving guidance, regulatory trends, and competitor activity to keep clients ahead of change. We provide actionable insights that inform strategy and help anticipate agency expectations before they become roadblocks.